Evidence map›Paper›PMID 34038741›Full record

ArticleAmerican journal of human genetics2021

Genetic effects on liver chromatin accessibility identify disease regulatory variants.

Kevin W Currin, Michael R Erdos, Narisu Narisu, Vivek Rai, Swarooparani Vadlamudi, Hannah J Perrin, Jacqueline R Idol, Tingfen Yan, Ricardo D'Oliveira Albanus, K Alaine Broadaway and 12 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Excessive CabioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Kevin W CurrinDepartment of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA.
Michael R ErdosNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Narisu NarisuNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Vivek RaiDepartment of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA.
Swarooparani VadlamudiDepartment of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA.
Hannah J PerrinDepartment of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA.
Jacqueline R IdolNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Tingfen YanNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Ricardo D'Oliveira AlbanusDepartment of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA.
K Alaine BroadawayDepartment of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA.
Amy S EtheridgeEshelman School of Pharmacy and Center for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599, USA.
Lori L BonnycastleNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Peter OrchardDepartment of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA.
John P DidionNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Amarjit S ChaudhryDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
NISC Comparative Sequencing ProgramNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Federico InnocentiEshelman School of Pharmacy and Center for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.
Erin G SchuetzDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Laura J ScottDepartment of Biostatistics and Center for Statistical Genetics, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA.
Stephen C J ParkerDepartment of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA; Department of Human Genetics, University of Michigan, Ann Arbor, MI 48109, USA.
Francis S CollinsNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Karen L MohlkeDepartment of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: mohlke@med.unc.edu.
University of North Carolina at Chapel Hill · USNational Institutes of Health · USUniversity of Michigan · USSt. Jude Children's Research Hospital · US

Funding

Inter- and Intra-Species Comparative SequencingZIBHG000196 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI THOMAS, JAMES · 2009 to 2025
$177.6M
Genetic analysis of type II diabetes in Finnish populationZIAHG000024 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI ERDOS, MICHAEL · 2009 to 2025
$38.2M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
University of Michigan Training Program in Genomic ScienceT32HG000040 · NHGRI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sebastian Zoellner · 1995 to 2026
$16.4M
UNC Initiative for Maximizing Student DevelopmentR25GM055336 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COOK, JEANETTE GOWEN, KASH, THOMAS L. · 1996 to 2023
$12.1M
Targeted Genetic Analysis of T2D and Quantitative TraitsR01DK072193 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAREN L. MOHLKE · 2005 to 2026
$11.3M
Pre-doctoral Training Program in Integrative Vascular BiologyT32HL069768 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Christopher P. Mack · 2002 to 2026
$9.7M
Bridging the gap between type 2 diabetes GWAS and therapeutic targetsUM1DK126185 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CLAUSSNITZER, MELINA C, GLOYN, ANNA LOUISE · 2020 to 2024
$9.5M
Genetic epidemiology of rare and regulatory variants for metabolic traitsR01DK093757 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAREN L. MOHLKE · 2011 to 2026
$8.2M
The Genetic Epidemiology of Heart, Lung, and Blood TraitsTraining Grant (GenHLB)T32HL129982 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Christy Leigh Avery, KAREN L. MOHLKE · 2016 to 2026
$3.8M
Context-specific and combinatorial genetic regulatory grammars in diabetesR01DK117960 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Stephen CJ Parker · 2018 to 2026
$2.8M
UNC Predoc Training Progr in Bioinformatics/Comp BiologyT32GM067553 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ELSTON, TIMOTHY C · 2005 to 2019
$2.5M
Intramural NIH HHS Z01 DK070004Intramural NIH HHS ZIA HG000024NHGRI NIH HHS T32 HG000040NHLBI NIH HHS F31 HL146121NHLBI NIH HHS T32 HL069768NHLBI NIH HHS T32 HL129982NIDDK NIH HHS HHSN267200700004CNIDDK NIH HHS P30 DK020572NIDDK NIH HHS R01 DK072193NIDDK NIH HHS R01 DK093757NIDDK NIH HHS R01 DK117960NIDDK NIH HHS U01 DK105561NIDDK NIH HHS UM1 DK126185NIGMS NIH HHS R25 GM055336NIGMS NIH HHS T32 GM067553NLM NIH HHS HHSN267200700004G
6 · The paper itself

Abstract

Identifying the molecular mechanisms by which genome-wide association study (GWAS) loci influence traits remains challenging. Chromatin accessibility quantitative trait loci (caQTLs) help identify GWAS loci that may alter GWAS traits by modulating chromatin structure, but caQTLs have been identified in a limited set of human tissues. Here we mapped caQTLs in human liver tissue in 20 liver samples and identified 3,123 caQTLs. The caQTL variants are enriched in liver tissue promoter and enhancer states and frequently disrupt binding motifs of transcription factors expressed in liver. We predicted target genes for 861 caQTL peaks using proximity, chromatin interactions, correlation with promoter accessibility or gene expression, and colocalization with expression QTLs. Using GWAS signals for 19 liver function and/or cardiometabolic traits, we identified 110 colocalized caQTLs and GWAS signals, 56 of which contained a predicted caPeak target gene. At the LITAF LDL-cholesterol GWAS locus, we validated that a caQTL variant showed allelic differences in protein binding and transcriptional activity. These caQTLs contribute to the epigenomic characterization of human liver and help identify molecular mechanisms and genes at GWAS loci.

Indexed as

Quantitative Trait LociAmino Acid MotifsBinding SitesChromatinChromatin Assembly and DisassemblyEnhancer Elements, GeneticGenetic VariationGenome-Wide Association StudyHumansLiverPromoter Regions, GeneticProtein BindingTranscription FactorsTranscriptomeChromatinTranscription FactorsATAC-seqcaQTLcardiometabolic traitschromatin accessibilityeQTLGWAStranscription factor motif

Identifiers

PMID34038741
PMCPMC8323023
OpenAlexW3164662861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.